Ordaōs is a human-enabled, machine-driven drug design company that creates novel and customized mini-proteins. Our mission is to help our biopharma partners develop safer and more effective life-saving treatments, that are easier and less expensive to develop, test and manufacture than traditional antibodies. Our proprietary technology, the Ordaōs Design Engine, leverages generative meta-learning to translate human-targeted product criteria into machine-designed mini-proteins.
Mini-proteins provide the power and performance of larger proteins while offering advantages over antibodies like greater stability, configurability, solubility, and developability. Ordaōs designs mini-proteins to create customized therapies for our partners that have ideal drug-like properties. Ordaōs is a generative mini-protein asset foundry that is providing a superior alternative to traditional therapeutics.
Mini-proteins provide the power and performance of larger proteins while offering advantages over antibodies like greater stability, configurability, solubility, and developability. Ordaōs designs mini-proteins to create customized therapies for our partners that have ideal drug-like properties. Ordaōs is a generative mini-protein asset foundry that is providing a superior alternative to traditional therapeutics.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Mini-protein therapeutic for HER2+ Breast Cancer
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
